Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
16.20
-0.28 (-1.70%)
Nov 17, 2026, 3:00 PM CST
SHA:600645 Revenue
Vcanbio Cell & Gene Engineering Corp., had revenue of 353.59M CNY in the quarter ending September 30, 2026, a decrease of -5.98%. This brings the company's total for the last twelve months to 1.38B, down -6.56% year-over-year. In the year 2025, Vcanbio Cell & Gene Engineering Corp., had annual revenue of 1.45B, down -8.23%. That makes Vcanbio Cell & Gene Engineering Corp., the 17,300th largest company in the world by revenue and 3,146th in China.
Revenue (ttm)
1.38B
Revenue Growth
-6.56%
P/S Ratio
5.46
Revenue / Employee
710.83K
Employees
1,935
Market Cap
7.39B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHA:600645 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.45B | -130.47M | -8.23% |
| Dec 31, 2024 | 1.59B | -4.30M | -0.27% |
| Dec 31, 2023 | 1.59B | 34.84M | 2.24% |
| Dec 31, 2022 | 1.55B | 19.56M | 1.27% |
| Dec 31, 2021 | 1.54B | 216.43M | 16.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.13B |
| Chengzhi | 10.74B |
| Pacific Shuanglin Bio-pharmacy | 2.42B |
| Novogene | 2.30B |
| Jiangxi Fushine Pharmaceutical | 1.97B |
| Aurisco Pharmaceutical | 1.67B |
| Chengdu Easton Biopharmaceuticals | 1.30B |
| Bio-Thera Solutions | 1.05B |